Search clinical trials for: Pyrotinib Maleate

Total 1052 results

xuexin he

Not yet recruiting

Adjuvant Dual Anti-HER2 Therapy in Patients With Small, Node-negative, HER2-positive Breast Cancer (SHERO)

HER2-positive Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Drug-drug Interaction Trial of Loperamide Pharmacokinetics Effect on Pyrotinib Maleate

Healthy Participants

China
The First Affiliated Hospital with Nanjing Medical...
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Pyrotinib in Women With High-risk in Early Stage Breast Cancer

HER2-positive Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Effect of Low-fat Diet on the Pharmacokinetics of Pyrotinib in Healthy Participants

Healthy Participants
Fujian Medical University

Not yet recruiting

A Study to Evaluate Inetetamab + Pyrotinib + Chemotherapy in Previously Untreated HER2-Positive Metastatic Breast Cancer

HER2-positive Recurrent/Metastatic Breast Cancer
Beijing Chest Hospital
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Real-World Study of Pyrotinib Maleate in the Treatment of Advanced/Metastatic Non-Small Cell Lung Cancer With Rare Mutations in HER2

HER2 Mutant Non-small Cell Lung Cancer
Zhongshan Hospital Xiamen University

Not yet recruiting

An Exploratory Basket Study of Pyrotinib Maleate Tablets in HER2 Mutated or Amplified of Metastatic Solid Tumors

Solid Tumor
The First Affiliated Hospital of Zhengzhou University
BeiGene; Jiangsu Hengrui Pharmaceutical Co., Ltd.; RemeGen Co., Ltd.

Not yet recruiting

Study of Tislelizumab Combined With DisitamabVedotin and Pyrotinib Maleate in HER2-positive or Mutated Advanced Colorectal Cancer Who Failed Standard Therapy

HER2-positive or Mutated Advanced Colorectal Cancer
Wuhan University

Not yet recruiting

Exploratory Study of Neoadjuvant Treatment of HER2-positive Breast Cancer With Py in Combination With HP

Breast Cancer
Henan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02)

Breast Neoplasms

China
Zhejiang Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Pyrotinib Combined With Docetaxel in the First-line Treatment of HER2-positive MBC

Metastatic Breast Cancer

China
Tianjin Medical University Cancer Institute and...

Completed

Pyrotinib Maleate Combined With Vinorelbine in the Treatment of HER2-positive Advanced Breast Cancer

HER2-positive Advanced Breast Cancer

China
Hunan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

Real-world Study of Pyrotinib in Neoadjuvant Therapy for HER2-positive Breast Cancer

HER2-positive Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Completed

Study of Pyrotinib in Patients With Human Epidermalgrowth Factor Receptor 2 (HER2) Positive Advanced Breast Cancer

Breast Cancer

China
Peking Union Medical College

Unknown

Pyrotinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer

Breast Cancer | HER2 Gene Mutation

China
Tongji University

Unknown

Efficacy and Safety of Pyrotinib in Patients With HER2 Mutation Advanced Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Tianjin Medical University Cancer Institute and...

Unknown

Phase 2 Study of Pyrotinib in Previously Treated Patients With NSCLC Having EGFR or ERBB2 Exon 20 Insertion Mutation

Non Small Cell Lung Cancer

China
Henan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

Study to Evaluate the Efficacy and Safety of SHR6390 Combined With Pyrotinib in HER2+ Advanced Breast Cancer (DAP-Her-01)

Metastatic Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Clinica Study of Pyrotinib in Patients of Advanced Non-Small Cell Lung Cancer With HER2 Mutation

Non Small Cell Lung

China
Hebei Medical University Fourth Hospital

Unknown

Pyrotinib in Combination With Nab-paclitaxel in Patients With HER2-positive Advanced Breast Cancer: an Exploratory Study

HER2-positive Breast Cancer
RemeGen Co., Ltd.

Not yet recruiting

A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation

Non-small Cell Lung Cancer

China
Caigang Liu
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients

HER2-positive Breast Cancer

China
Second Affiliated Hospital, School of Medicine,...
Zhejiang Cancer Hospital; First Affiliated Hospital of Zhejiang University; Sir... and other collaborators

Unknown

A Clinical Study of Pyrotinib in Patients With HER2-positive Advanced Colorectal Cancer

Colorectal Cancer

China
National University of Malaysia

Recruiting

Comparison of Modified Vacuum-formed Retainers Versus Hawley Retainer

Clinical Trial | Orthodontic Retainers

Malaysia
Guangdong Association of Clinical Trials
Chinese Thoracic Oncology Group

Recruiting

Phase II Umbrella Study Directed by Next Generation Sequencing (TRUMP)

Carcinoma, Non-Small-Cell Lung

China
The First Affiliated Hospital with Nanjing Medical...
First Affiliated Hospital of Wenzhou Medical University

Recruiting

A Phase II Clinical Study of Treatment With Disitamb Vedotin Plus Pyrotinib in HER2-positive Early Breast Cancer

Breast Cancer

China
Sun Yat-sen University

Recruiting

Inetetamab in Combination With Pyrotinib in HER2 Mutant or Amplified Advanced Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Hengrui Therapeutics, Inc.

Unknown

Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors

Breast Cancer | Gastric Cancer | NSCLC | Solid Tumors

United States
Yongchang Zhang

Recruiting

PD-1 Combined With Pyrotinib for Chemotherapy Failure HER2 Insertion Mutation Advanced NSCLC

HER2 Insertion Mutation Positive Advanced NSCLC

China
Biyun Wang, MD

Completed

18F-FDG Uptake Heterogeneity Predicts Pyrotinib Response

HER2-positive Breast Cancer

China
Fudan University
GeneQuantum Healthcare (Suzhou) Co., Ltd.

Recruiting

GQ1001 Combined With Pyrotinib for Treatment With HER2 Positive Metastatic Breast Cancer

Advanced/ Metastatic Her-2 Positive Breast Cancer

China
Taizhou Hospital

Recruiting

Pyrotinib After Trastuzumab-based Adjuvant Therapy in Patients With HER2-positive Breast Cancer

Breast Cancer

China
Sun Yat-sen University

Recruiting

Pyrotinib Plus Vinorelbine in Participants With HER2-positive Previously Treated Locally Advanced or Metastatic Breast Cancer

Breast Cancer | Breast Diseases | HER2-positive Breast Cancer | Vinorelbine | Pyrotinib

China
Hunan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Pyrotinib in Combination With Letrozole in Patients With HER2-Positive, ER-Positive Metastatic Breast Cancer

Metastatic Breast Cancer

China
RenJi Hospital

Recruiting

Continuous or Intermittent Extension of Adjuvant Pyrotinib for Invasive HER2-positive Breast Cancer (CORINNE-PI)

Breast Cancer Invasive

China
Shengjing Hospital
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study of SHR-A1811 Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients

HER2-positive Breast Cancer

China
RenJi Hospital

Recruiting

Adjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer (ATP)

Locally Advanced Breast Cancer

China
RenJi Hospital

Active, not recruiting

Neoadjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer (NeoATP)

Breast Cancer Female

China
The First Affiliated Hospital with Nanjing Medical...

Active, not recruiting

Treatment With Pyrotinib-Based Therapy in Lapatinib Resistant HER2-Positive Metastatic Breast Cancer

Breast Cancer

China
Sun Yat-sen University
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Study to Evaluate the Efficacy and Safety of CDK4/6 Inhibitor SHR6390 Combined With Pyrotinib in the Treatment of HER2-positive Advanced Breast Cancer

Metastatic Breast Cancer
Shengjing Hospital

Active, not recruiting

Pyrotinib Maleate, CDK4/6 Inhibitor and Letrozole in Combination for Stage II-III TPBC: a Phase II Trial

Breast Cancer

China
Peking Union Medical College Hospital

Recruiting

Phase II Clinical Study of Pyrotinib in First-line Treatment of Primary HER2-amplified/Mutated Advanced Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer

Advanced Non-small Cell Lung Cancer

China
Fudan University

Recruiting

Efficacy and Safety of Pyrotinib in HER2 Positive Gastrointestinal Tumors

Effect of Drug | Gastrointestinal Tumor

China
Fudan University

Recruiting

Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast Cancer

Breast Cancer Stage I

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Study Evaluating Pyrotinib/Pyrotinib in Combination With Docetaxel in Patients With HER2+ Advanced Gastric Cancer

HER2 Positive Gastric Cancer

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Fulvestrant or Capecitabine Combined With Pyrotinib in HR+/HER2+ Metastatic Breast Cancer

Breast Cancer

China
Peking University Cancer Hospital & Institute

Not yet recruiting

Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy for HR +/HER2 + Advanced Breast Cancer

Breast Neoplasm Female
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Study of Evaluating The Effects Of Pyrotinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer

Breast Cancer

China
Tianjin Medical University Second Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

The Basket Study of Pyrotinib Maleate for HER2-Postive Solid Tumor

Solid Tumor | HER-2 Gene Amplification | HER2 Gene Mutation | HER-2 Protein Overexpression

China

3

Subscribe